In the original article, there was a mistake in Figure 4A as published. The figure text was mislabeled, and a lane-line was missing. The corrected Figure 4 appears below.
Figure 4
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s Note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Summary
Keywords
Hippel-Lindau protein (pVHL), hypoxia inducible factor, mitochondria, bioenergetics, metabolism, CHCHD4, respiratory chain
Citation
Briston T, Stephen JM, Thomas LW, Esposito C, Chung Y-L, Syafruddin SE, Turmaine M, Maddalena LA, Greef B, Szabadkai G, Maxwell PH, Vanharanta S and Ashcroft M (2021) Corrigendum: VHL-Mediated Regulation of CHCHD4 and Mitochondrial Function. Front. Oncol. 11:740273. doi: 10.3389/fonc.2021.740273
Received
12 July 2021
Accepted
26 August 2021
Published
23 September 2021
Volume
11 - 2021
Edited and reviewed by
Keith R. Laderoute, Consultant, Redwood City, CA, United States
Updates
Copyright
© 2021 Briston, Stephen, Thomas, Esposito, Chung, Syafruddin, Turmaine, Maddalena, Greef, Szabadkai, Maxwell, Vanharanta and Ashcroft.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Margaret Ashcroft, m.ashcroft@medschl.cam.ac.uk
‡These authors have contributed equally to this work
†Present Address: Thomas Briston, Hatfield Research Laboratories, Neurology Innovation Centre, Eisai Ltd., Hatfield, United Kingdom
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.